Drug firm Wockhardt today said it has received final approval from the US health regulator for marketing generic bupropion hydrochloride tablets used for treating depression and is launching the product immediately.
The company has received final approval from the United States Food & Drug Administration (USFDA) for marketing bupropion hydrochloride 12-hr extended release tablets in the strengths of 100 mg, 150 mg and 200 mg, Wockhardt said in a statement.
Bupropion tablets are generic version of Glaxo Smithkline's Wellbutrin SR tablets.
Commenting on the approval, Wockhardt Founder Chairman and Group CEO Habil Khorakiwala, said, "This is our sixth ANDA approval in past two weeks and Bupropion SR 12-Hr is yet another product based on extended-release technology."
Citing IMS Health data, the company said the total market for this product in the American market is about $268 million.
The product will be manufactured at the company's facility at Waluj in Maharashtra, it added.
Shares of Wockhardt were toady trading at Rs 1,223.60 per scrip in the afternoon trade on BSE, up 0.04% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app